Bone Marrow Biopsy From a 32-Year-Old Patient

Poll

A 32-year-old man presents with malaise and fatigue. A bone marrow biopsy is performed. What is your diagnosis?

A 32-year-old man presents with malaise and fatigue. A bone marrow biopsy is performed.

What is your diagnosis?

A. Metastatic small-cell carcinoma
B. Chronic lymphocytic leukemia
C. Merkel cell carcinoma
D. Chronic myeloid leukemia
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Related Content
More than half of evaluable patients in the phase 1/2 NEXICART-2 trial experienced organ responses following treatment with NXC-201.

NXC-201 Yields Rapid Responses in Small R/R AL Amyloidosis Cohort

Russ Conroy
December 8th 2025
Article

More than half of evaluable patients in the phase 1/2 NEXICART-2 trial experienced organ responses following treatment with NXC-201.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Survival Similar With MMUD Grafts in GVHD Care Regardless of Match Level

Roman Fabbricatore
December 6th 2025
Article

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

American Society for Transplantation and Cellular Therapy
November 24th 2025
Article

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.

Tandem CAR T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time

Tandem CAR T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time

American Society for Transplantation and Cellular Therapy
November 24th 2025
Article

Researchers have demonstrated that a tandem CAR T cell targeting mesothelin and MUC16 ectodomain is able to outmaneuver tumor heterogeneity, outperforming single target CAR T cells in mixed ovarian and pancreatic models.